Physician profile
James E Myers
NPI 1447440177
$1,215.85
in general payments reported to CMS, 2019-2025
19 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.87 · 2022: $33.30 · 2023: $35.16 · 2024: $385 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $146.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $141.37 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $122.20 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $98.91 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $91.78 | 2024-2025 | Farxiga |
| Abbvie INC. | $87.75 | 2025 | |
| Abbott Laboratories | $74.59 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $74.24 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $66.50 | 2024-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $61.87 | 2019 | |
| Phathom Pharmaceuticals, INC. | $57.95 | 2024-2025 | Voquezna |
| Amgen INC. | $54.43 | 2025 | Repatha, Otezla, Krystexxa |
| Sanofi-Aventis U.S. LLC | $24.58 | 2025 | |
| Axsome Therapeutics, INC. | $23.60 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.77 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $17.41 | 2025 | Lagevrio |
| Capsovision, INC. | $15.22 | 2025 | Capsocam Plus |
| Tolmar, INC. | $13.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.